title: A prospective multicenter trial with human recombinant alpha 2c-interferon in hairy cell leukemia before and after splenectomy.
abstract: Our multicenter study on the treatment of hairy cell leukemia (HCL) started in December 1984 and the present data cover the time up to June 30, 1986. Ninety-seven patients were enrolled. For induction of response daily doses (6 micrograms) of low dose human recombinant alpha 2c-interferon (arg) was chosen. Further dose reduction (3 micrograms) was possible for patients who improved within the first 3-4 weeks. Patients with known risk factors started at lower doses (0.6 microgram daily). As infections are known to be the main cause of death in HCL, splenectomy was not mandatory before treatment. Thirty-nine patients received treatment with interferon. Nevertheless, infections remained the major cause of death in the study. The protocol did not prevent fatal infections in nine of the 34 splenectomized patients. The regimen proved safe for all but one of the nonsplenectomized patients. According to this experience, new criteria are needed for the choice of primary treatment in HCL. In our opinion splenectomy should become restricted to selected cases.
authors: German Multicenter Study Group for Treatment of Hairy Cell Leukemia, Giessen.
authors: H
authors: H
authors: Pralle
authors: T
authors: T
authors: Zwingers
authors: S
authors: S
authors: Boedewadt
authors: K
authors: K
authors: Bross
authors: B
authors: B
authors: Dörken
authors: H
authors: H
authors: Gamm
authors: A D
authors: AD
authors: Ho
authors: R M
authors: RM
authors: Parwaresch
authors: N
authors: N
authors: Schmitz
authors: U
authors: U
authors: Papendick
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000150:complications; D003131:Combined Modality Therapy; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007943:Leukemia, Hairy Cell / Q000628:therapy*; D009894:Opportunistic Infections / Q000150:complications; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D013156:Splenectomy / Q000009:adverse effects; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D007370:Interferon Type I; D011994:Recombinant Proteins